

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Dated: 01<sup>st</sup> July, 2021

To,  
**BSE Limited**  
PhirozeJeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai-400001  
Email ID: corp.relations@bseindia.com

**Ref: Genomic Valley Biotech Limited (539206/ GVBL)**

**Sub: Submission of Newspaper Advertisements of the Extract of Audited Financial Results approved in Board Meeting of the Company held on 29.06.2021**

Dear Sir/Madam,


Pursuant to the Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper advertisements of the Extract of Audited Financial Results for the quarter and year ended 31.03.2021 approved in Board Meeting of the Company held on 29.06.2021.

Kindly take the above information into your records.

Thanking you.

Yours faithfully,

For **Genomic Valley Biotech Limited**



**Yogesh Agrawal**  
**Managing Director**  
**DIN: 01165288\***  
**Add: G-74, Pushkar Enclave,**  
**Paschim Vihar Delhi - 110063**

# ILMS & TECHNOLOGIES LIMITED

1203, Vijaya Building 17, Barakhamba Road, Connaught Place, New Delhi-110001  
 11-120-4227792, Fax: +91-120-4227791, Website: www.bgilfilms.com  
 Audited Yearly Financial Results for the Quarter / Year ended 31st March, 2021  
 (Rs. in Lacs)

THURSDAY, JULY 1, 2021

WWW.FINANCIAREXPRESS.COM

18

FINANCIAL EXPRESS

3. Net Profit / (Loss) for the period before tax after Exceptional/Extraordinary items	(13.46)	(0.40)	6.72	2.29
4. Net Profit / (Loss) for the period after tax (after Exceptional items)	(9.92)	0.22	8.67	1.52
5. Total Comprehensive Income for the period (Comprising profit / (Loss) for the period (after tax) and other comprehensive income (after tax))	(9.92)	0.22	8.67	1.52
6. Equity Share Capital	499.80	499.80	499.80	499.80
7. Reserve (Excluding Revaluation Reserves) as shown in the Audited Balance Sheet of previous year				
8. Earning Per Share (Face Value of Rs. 1/- each) (for continuing and discontinued operations)				
a Basic	-0.02	0.00	0.017	0.000
b Diluted	-0.02	0.00	0.017	0.000

NOTE: The above is an extract of the detailed format of the financial results for the Quarter ended 31st March, 2021, filed with the Stock Exchanges. The full format of the financial results is available on the website of the Stock Exchange www.bseindia.com and on Company's website www.abhinavleaseinfintd.in

For Abhinav Leasing and Finance Limited

Date: 29.06.2021  
 Place: New Delhi

Sd/-  
 Mamta Agarwal (Managing Director)

## GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. Stone, Barri Chharrha Road, Village- Kherka Musalman, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507  
 CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542  
 Email: genomicvalley@gmail.com; Visit: http://www.genomicvalley.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS  
 FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021 (Amount in ₹)

Sr. No.	Particulars	Quarter ended			Year ended	
		31-Mar-21 Audited	31-Dec-20 Un-Audited	31-Mar-20 Audited	31-Mar-21 Audited	31-Mar-20 Audited
1	Total Income from operation	246,116	916,620	2,987,500	2,110,028	8,606,499
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	-3,263,376	-136,263	803,805	-5,018,143	2,057,310
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Item)	-3,263,376	-136,263	803,805	-5,018,143	2,057,310
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Item)	-3,835,747	-136,263	1,606,422	-5,590,514	2,859,927
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	-3,835,747	-136,263	1,606,422	-5,590,514	2,859,927
6	Equity Share Capital (30,54,500 Equity Shares @ Rs. 10 each)	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	14,334,645	19,925,159
8	Earnings Per Share					
	(a) Basic	-1.26	-0.04	0.53	-1.83	0.94
	(b) Diluted	-1.26	-0.04	0.53	-1.83	0.94

Notes:  
 1 The above extracts of Financial Results were reviewed by the Members of Audit Committee and were thereafter approved by the Board of Directors at their respective Meeting held on June 29, 2021.  
 2 The above is an extract of the detailed format of quarterly and yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and yearly Financial Results are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.genomicvalley.com).

For and on behalf of the Board of Genomic Valley Biotech Ltd

Sd/-  
 Yogesh Agrawal  
 (Managing Director)  
 DIN-01165288

Place: Delhi  
 Dated: June 29, 2021

Add: G-7A Pushkar Enclave Paschim Vihar, New Delhi-110063

## MARKTESH TRADING LIMITED

REGD. OFFICE : 612, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI-110019  
 CIN: L51909DL2005PLC135119, E-mail: shrikantnaralade@gmail.com, Tel/Fax: +91-11-26219944  
 Statement of Audited Fin. Res. for the 4th. Qtr. & Year ended 31st. March, 2021  
 (Rs. in Lacs)

PARTICULARS	Quarter ended			Year Ended		Particulars	Three months ended 31/03/2021
	(31/03/2021) (Audited)	(31/12/2020) (Un-audited)	(31/03/2020) (Audited)	Yearly figures Current Period ended (31/03/2021)	Yearly figures Current Period ended (31/03/2020)		
I. Revenue from Operations	30.40	25.50	28.43	67.69	65.14		
II. Other Income	2.66	1.56	5.96	7.53	10.51		
III. Total Revenue (I+II)	42.06	27.06	34.39	75.62	75.65		
IV. Expenses							
(a) Cost of Materials consumed	0	0	0	0	0		
(b) Purchase of stock-in-trade	36.39	18.65	34.38	65.34	73.69		
(c) Changes in Inventories of finished goods, work in progress and stock-in-trade	(59.90)	6.84	(3.54)	(56.62)	(6.48)		
(d) Employee benefits expense	1.54	0.92	1.06	4.66	3.81		
(e) Finance cost	0	0	0	0	0		
(f) Depreciation and amortisation expense	0.07	0.06	0.05	0.23	0.23		
(g) Other expenses	1.27	0.38	1.73	2.58	3.63		
Total Expenses	19.63	26.61	33.7	13.21	78.78		
V. Profit/(Loss) before exceptional and extraordinary							

(Formerly Known as SU)  
 Regd office: 1502, 15th Floor, RG Trade Tower, N  
 Phone: 011 - 45824477, We  
 CIN: L74900D

## EXTRACT OF STANDALONE FOR THE FOURTH QUARTER A

Sl. No.	Particulars
1	Total Income from Operations
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)
3	Net Profit/(Loss) for the period before Tax (After Exceptional and/or Extraordinary Items)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)
5	Total Comprehensive Income for the period (Comprising for the period (after tax) and other Comprehensive income)
6	Equity Share Capital
7	Reserves (excluding Revaluation Reserve) as shown in Balance Sheet of the previous year
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)- 1. Basic: 2. Diluted:

Note:  
 A) The above is an extract of the detailed format of Audited Financial Results filed with the Metropolitan Stock Exchange of India Limited (Disclosure Requirements) Regulations, 2015. The full format of Stock Exchange website www.mseai.in and on the company  
 B) The above Audited Financial Results have been reviewed Board of Directors of the Company at their 3/2021 Board quarter and year ended March 31, 2021 have been Audited

For USS Glo

Place: New Delhi  
 Date: 28th June, 2021

## SAINIK FINANCE & I

Regd.off: 129 Transport Centre, Rohtak Road, Punjabi Bagh  
 Corp.Off: 7th Floor, Office Tower, Ambience Mall, NH-8, Gurgaon  
 CIN: L26912DL1991PLC046449,  
 Email: info@sainik.org, legal

## Extract of Statement of Standalone for the quarter ended

Sl. No.	Particulars	3 months ended (Audited)
		31.03.20
1	Total Income from operations	25.3
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary Items)	(1,070.55)
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary Items)	(1,070.55)
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary Items)	(768.57)
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)	(768.57)
6	Equity Share Capital (face value of the share: Rs.10 each)	1,088.0
7	Reserves (excluding Revaluation Reserve) as per previous financial year	
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations) 1. Basic : 2. Diluted :	(7.06) (7.06)

Notes:-

दस्तावेजों को अपलोड करें।  
 7. सदस्यों से अनुरोध है कि वे एजीएम की सूचना में दिये गये सभी नोट्स और विशेषकर एजीएम में शामिल होने के लिए निर्देश, रिपोर्ट ई-वोटिंग या एजीएम में ई-वोटिंग के माध्यम से वोट देने की प्रक्रिया को भली-भांति पढ़ लें।  
 निदेशक मंडल के आदेशानुसार  
 कृते आईसीआरए लिमिटेड  
 (एस. शकेत्र रहमान)  
 स्थान : पुरल्लाम  
 तिथि : 30 जून, 2021  
 कंपनी सचिव और अनुपालन अधिकारी

आइडिएफएस फस्ट बैंक लिमिटेड  
 पूर्व का कैपिटल फस्ट लिमिटेड, आईडीएफसी बैंक लिमिटेड  
 वर्तमान में आईडीएफसी फस्ट बैंक लिमिटेड के नाम से।  
 तिथि : 30 जून, 2021

**जीनोमिक वैली बायोटेक लिमिटेड**  
 पंजीकृत कार्यालय : 4 के.एम. स्टोन, बेरी छर्मा रोड, ग्राम-खेड़का मुसलमान, पो.ऑ. टांदाहेड़ी,  
 तहसील-बहादुरगढ़, जिला-झज्जर, हरियाणा-124507  
 सीआईएन: L01122HR1994PLC033029; दूरभाष : 491-9811341542  
 ई-मेल: genomicvalley@gmail.com; वेबसाइट: http://www.genomicvalley.com  
 31 मार्च, 2021 को समाप्त तिमाही तथा वर्ष के स्टैंडएलोन लेखापरीक्षित  
 वित्तीय परिणामों का विवरण

क्र. सं.	विवरण	समाप्त तिमाही		समाप्त वर्ष		
		31-मार्च-21 लेखापरीक्षित	31-दिस-20 अलेखापरीक्षित	31-मार्च-20 लेखापरीक्षित	31-मार्च-21 अलेखापरीक्षित	31-मार्च-20 लेखापरीक्षित
1	प्रचालनों से कुल आय	246,116	916,620	2,987,500	2,110,026	8,606,499
2	अवधि हेतु निवल लाभ/(हानि) (कर, अपवादित तथा/अथवा असाधारण मदों से पूर्व)	-3,263,376	-136,263	803,805	-5,018,143	2,057,310
3	कर पूर्व अवधि हेतु निवल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के परचात)	-3,263,376	-136,263	803,805	-5,018,143	2,057,310
4	कर परचात अवधि हेतु निवल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के परचात)	-3,835,747	-136,263	1,606,422	-5,590,514	2,859,927
5	अवधि हेतु कुल व्यापक आय [अवधि हेतु लाभ/(हानि) (कर परचात) तथा अन्य व्यापक आय (कर परचात) सहित]	-3,835,747	-136,263	1,606,422	-5,590,514	2,859,927
6	इनिशियल शेयर पूंजी (30,54,500 इनिशियल शेयर रु. 10 प्रत्येक)	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500
7	आरक्षितियाँ (पुनर्मुख्यकरण आरक्षितियों को छोड़कर) जैसा कि मत वर्ष के लेखापरीक्षित तुलन पत्र में प्रदर्शित है।				14,334,645	19,925,159
8	आय प्रति शेयर					
	(क) बेसिक	-1.26	-0.04	0.53	-1.83	0.94
	(ख) डायल्यूटेड	-1.26	-0.04	0.53	-1.83	0.94

**Notes:**  
 1. उपर्युक्त वित्तीय परिणामों के सारांश की समीक्षा ऑडिट कमेटी द्वारा की गयी थी और उसके परचात 29 जून, 2021 को आयोजित निदेशक मण्डल की बैठक में उनके द्वारा अनुमोदित की गयी थी।  
 2. उपर्युक्त सेवा (सूचीबद्धता दायित्व तथा प्रकटन अपेक्षार) विनियम, 2015 के विनियम 33 के अनुसार स्टॉक एक्सचेंजों के साथ दर्ज तिमाही तथा वर्ष के वित्तीय परिणामों के विस्तृत प्रारूप का सारांश है। तिमाही तथा वर्ष के वित्तीय परिणामों का पूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइट (www.bseindia.com) तथा कम्पनी की वेबसाइट (www.genomicvalley.com) पर उपलब्ध है।

जीनोमिक वैली बायोटेक लिमिटेड के लिए तथा उनकी ओर से  
 ह./-  
 योगेश अग्रवाल  
 (प्रबन्ध निदेशक)  
 स्थान : दिल्ली  
 तिथि : 29 जून, 2021  
 पता : जी-74, पुष्कर एन्कलेव, पश्चिम विहार, नई दिल्ली-110063  
 सीआईएन : 01165288

Delhi-110006

MARCH 31, 2021

(Rs. In lacs)

Consolidated

Quarter ended	For the year ended		
	March	March	March
20	31, 2020	31, 2021	31, 2020
Audited	Audited	Audited	Audited
	(Refer Note 9)		
231	1,168	4,740	18,609
77	(494)	(1,741)	(2,746)
77	(494)	(1,741)	(2,746)
303	(523)	(1,784)	(2,931)
	-	-	-
	-	-	-
603	(523)	(1,784)	(2,931)
614	(470)	(1,712)	(2,931)
1,868	1,868	1,868	1,868
	-	(3,774)	(2,063)
3.23	(2.80)	(9.55)	(15.69)
	-	-	-
3.23	(2.80)	(9.55)	(15.69)

s) held on June 29, 2021. The Audit Report of the  
 k Exchanges (i.e. BSE Limited and National Stock  
 time to time. The full format of the Standalone and  
 www.dcm.in.  
 For and on behalf of the Board  
 For DCM Limited  
 Sd/-  
 Jitendra Tuli  
 Managing Director